Prosecution Insights
Last updated: October 02, 2026
Application No. 18/549,281

CRYSTALLINE FORMS OF (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUORO-METHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE

Final Rejection §112
Filed
Sep 06, 2023
Priority
Mar 09, 2021 — EU 21161489.6 +1 more
Examiner
CHEN, PO-CHIH
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bayer Aktiengesellschaft
OA Round
2 (Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
572 granted / 771 resolved
+14.2% vs TC avg
Moderate +15% lift
Without
With
+14.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
51 currently pending
Career history
806
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
33.4%
-6.6% vs TC avg
§102
19.0%
-21.0% vs TC avg
§112
30.8%
-9.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 771 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAIL ACTION This office action is a response to Applicant’s amendments/remarks after non-final rejection filed 5/22/2026. As filed, claims 1 and 4-14 are pending; and claims 2 and 3 are cancelled. Information Disclosure Statement The information disclosure statement (IDS) submitted on 7/29/2026 has been considered by the Examiner. Response to Amendments/Remarks Applicant’s amendments/remarks, filed 5/22/2026, with respect to claims 1 and 4-14, have been fully considered and are entered. The status for each rejection in the previous Office Action is set out below. The objection to the specification is withdrawn per amendments. The § 112(b) indefinite rejection of claim 8 regarding, “the amorphous form”, is withdrawn per amendments. The § 112(b) indefinite rejection of claim 8 regarding, “the crystalline modification A”, is maintained because the abovementioned phrase still lacked antecedent basis. The § 112(b) indefinite rejection of claims 9-11 is withdrawn per amendments. The claim objection of claims 1, 4-9, 13, and 14 is withdrawn per amendments. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 8-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 8 the claim recites the phrase, “the crystalline modification A” wherein the word, “the”, requires antecedent basis, and it is unclear where applicant has defined “a” crystalline modification A. Without antecedent basis, the claim is rendered indefinite. In addition, the claim recites, “the crystalline modification A”, of instant formula (II) without providing any PXRD pattern. It is unclear to the Examiner what are the metes and bounds of the crystalline modification, based on only the abovementioned name (i.e. A). As a result, the claim does not stand alone, and one must refer back to the specification to define the claimed invention to determine the metes and bounds of the claim. Again, the claim is rendered indefinite. Regarding claims 9 and 10, the claims are dependent of claim 8, and they failed to correct the indefiniteness issue of claim 8, which rendered these claims indefinite. Claim Objections Claim 9 is objected to because of the following informalities: Regarding claim 9, the claim recites the phrase, “and C1-C4 organic alcohols mixture thereof, and mixtures of the solvents with water”. Such expression can be clarified by reciting -- 1-C4 organic alcohols, mixture thereof, and mixtures of the inert solvents with water --. Appropriate correction is required. Allowable Subject Matter Claims 1, 4-7, and 11-14 are allowed. Conclusion Claims 8-10 are rejected. Claims 1, 4-7, and 11-14 are allowed. Claim 9 is objected. Claims 2 and 3 are cancelled. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to PO-CHIH CHEN whose telephone number is (571)270-7243. The examiner can normally be reached Monday - Friday 10:00 am to 6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PO-CHIH CHEN/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Sep 06, 2023
Application Filed
Feb 26, 2026
Non-Final Rejection mailed — §112
May 22, 2026
Response Filed
Aug 21, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12729209
MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT
3y 5m to grant Granted Sep 08, 2026
Patent 12715852
PREPARATION OF OPTICALLY ACTIVE ENANTIOMERS OF PIPERONYL AMINES BY RESOLUTION OF THE DIASTEREOMERIC SALTS
3y 11m to grant Granted Aug 25, 2026
Patent 12714693
USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS
1y 8m to grant Granted Aug 25, 2026
Patent 12703676
SYSTEMS AND METHODS FOR PRODUCING NITRILES
2y 2m to grant Granted Aug 11, 2026
Patent 12691101
NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT
4y 9m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
89%
With Interview (+14.8%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 771 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month